A new device on the market for patients with heart failure is the first device in cardiology to receive a “breakthrough” designation by the Food and Drug Administration.
is the first device in cardiology to receive a “breakthrough” designation by the Food and Drug Administration.
For many patients with heart failure who are already on the right medications, there’s not much else they can do unless they decide to undergo open-heart surgery to place a mechanical pump inside. The new device, however, called the and approved by the FDA on March 21, is a device that can improve advanced stages of the disease by helping the heart squeeze more effectively.in the United States. As the heart’s ability to pump blood to the rest of the body deteriorates, the heart becomes unable to squeeze and fluid builds up in the body. This fluid can accumulate in the lungs, causing shortness of breath, or throughout the tissues of the body, causing generalized swelling.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
FDA says cybersecurity vulnerabilities found in some Medtronic devicesThe U.S. Food and Drug Administration (FDA) on Thursday said cybersecurity vulne...
Weiterlesen »
FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetesThe U.S. Food and Drug Administration declined to approve a drug developed by Sa...
Weiterlesen »
FDA Rejects Oral Treatment for Type 1 DiabetesLexicon Pharmaceuticals is developing the treatment, which is called Zynquista, with French pharmaceutical giant Sanofi.
Weiterlesen »
Outgoing FDA chief: Altria bait-and-switched me with $12.8 billion Juul investmentFood and Drug Administration (FDA) Commissioner Scott Gottlieb said on Tuesday that tobacco giant Altria went back on its promise to clamp down on vape pods with its $12.8 billion investment in e-cigarette decacorn Juul Labs.
Weiterlesen »
Jazz Pharma's sleep disorder treatment gets FDA nodThe U.S. Food and Drug Administration approved Jazz Pharmaceuticals Plc's t...
Weiterlesen »
Sage Therapeutics’ Drug for Postpartum Depression Gets FDA NodU.S. health regulators on Tuesday approved Sage Therapeutics Inc.’s Zulresso, the first medication specifically intended for women with postpartum depression.
Weiterlesen »
FDA approves first treatment for postpartum depressionThe FDA has approved a new medication called Zulresso, a completely new class of drug designed specifically to treat postpartum depression. It’s a one-time infusion given in a hospital over two and a half days.
Weiterlesen »
FDA issues warning to two breast implant makers over safety concernsLess than a week before a major hearing on breast implant safety, the FDA issued two warning letters to implant manufacturers, citing their failure to do proper safety studies.
Weiterlesen »
FDA approves the first drug designed to treat postpartum depressionThe FDA approved the first drug specifically for postpartum depression, a debilitating condition that affects about 400,000 women a year in the United States.
Weiterlesen »